TNF and irritable bowel syndrome: For inflammatory bowel disease (IBD), this primarily encompasses the approved anti-tumor necrosis factor (TNF) therapies (infliximab, adalimumab, certolizumab, golimumab), but also agents approved, or under development, that target integrins (natalizumab, vedolizumab) and interleukin (IL)-12/23 (ustekinumab), amongst others.